Veracyte (VCYT) Q4 2025 earnings review
Stellar Testing Growth Funds a Strategic Reinvestment Phase
Veracyte capped off an exceptional 2025 with Q4 revenue accelerating 19% YoY to $140.6M, driven entirely by its core diagnostic testing engines, Decipher and Afirma. The company's profitability has reached record levels, with Non-GAAP gross margin expanding to 75.1% and Adjusted EBITDA margin holding steady at a best-in-class 30.1%. Operating cash flow was a massive $52.6M for the quarter alone. However, investors need to look past the immediate beat: 2026 guidance signals a deliberate margin compression. Management is projecting Adjusted EBITDA margins to reverse back down to ~25% as they aggressively reinvest cash to launch TrueMRD and the Prosigna LDT. The core business is a cash-printing machine, but 2026 shifts the narrative from margin expansion to execution risk in new clinical markets.
🐂 Bull Case
Testing revenue accelerated to 21% YoY growth in Q4 ($135.8M). Decipher volume grew 21% and Afirma volume grew 12%, proving the company can continue to capture market share in its legacy indications.
Veracyte generated $136.3M in operating cash flow in FY25 ($52.6M in Q4 alone). With $412.9M in cash and short-term investments, the company has a fortress balance sheet to fund pipeline launches without dilution.
🐻 Bear Case
After climbing from 21.6% in 25Q1 to 30.1% in H2 2025, Adjusted EBITDA margin is guided down to ~25% for 2026. Management is sacrificing near-term profitability to fund aggressive commercial expansions.
Biopharmaceutical and other revenue collapsed from $3.5M in 24Q4 to $1.0M in 25Q4 due to the restructuring of the French subsidiary. This creates an ongoing drag on total revenue growth.
⚖️ Verdict: 🟢
Bullish. The 2026 margin contraction is a deliberate, fully-funded strategic choice rather than structural deterioration. The core Decipher and Afirma franchises are performing flawlessly, providing a high-margin safety net as the company enters its next growth phase.
Key Themes
Decipher Franchise Dominance
Decipher continues to be Veracyte's primary growth engine. Q4 revenue grew an accelerating 27% YoY to $85.6M, driven by a 21% increase in test volume (27,200 tests). The test has now posted consistently high double-digit growth for over three years, benefiting from expansion into metastatic populations and broad NCCN guideline support.
Planned Margin Compression for Launch Cycle
The defining narrative for 2026 is a reversing profitability trend. Adjusted EBITDA margins peaked at 30.1% in Q3 and Q4 of 2025. However, FY26 guidance projects ~25%. This 500 basis point compression represents aggressive OpEx deployment to support the commercial launches of the Prosigna LDT and TrueMRD platforms. Execution risk is now elevated—the ROI on this spending must materialize to justify the margin sacrifice.
Afirma Cost Efficiency Breakthroughs
Despite being a mature asset, Afirma delivered stable 12% volume growth and 16% revenue growth in Q4. More importantly, the completed transition to the v2 transcriptome is acting as a massive gross margin lever. Non-GAAP gross margin for the total company accelerated to 75.1% in Q4 (up from 69.3% a year ago), validating management's strategy of platform consolidation.
Biopharma Revenue Liquidation
The strategic decision to liquidate the French subsidiary (Veracyte SAS) has triggered a steep deceleration in the biopharmaceutical segment. Q4 biopharma revenue plummeted 72% YoY to just $1.0M. While exiting this low-margin business improves the overall corporate profile, it creates a lingering mathematical headwind on total consolidated revenue growth heading into 2026.
Clinical Evidence Moat Deepens
Veracyte leverages data as a competitive weapon. The company announced over 15 abstracts featuring Decipher Prostate and Decipher Bladder at the upcoming ASCO GU meeting. Furthermore, TrueMRD's inclusion in the HCRN GU 20-444 response-guided trial signals critical early validation for the whole-genome platform ahead of its commercial debut.
Other KPIs
Accelerating dramatically. The company generated more cash from operations in Q4 ($52.6M) than it did in the entire first nine months of the year ($83.7M). For the full year, OCF hit $136.3M, an 81% improvement YoY, proving the immense operating leverage inherent in the mature testing portfolio.
While GAAP Net Income looks artificially massive (up 705% YoY), investors must note this includes a $12.6 million positive adjustment related to contingent consideration (likely tied to C2i/NanoString). However, even excluding this, Non-GAAP Net Income was exceptionally strong at $42.8M.
Guidance
Decelerating. The midpoint of $576M implies ~11.5% YoY growth, down from the 16% total revenue growth achieved in FY25. This deceleration is primarily due to the ongoing phase-out of the biopharma revenue segment and challenging comparisons.
Stable to slightly decelerating. Implies 14-16% YoY growth. Crucially, management noted this guidance explicitly excludes any contribution from new tests (TrueMRD, Prosigna). This means the core Decipher and Afirma franchises are expected to carry the entire growth burden for another year.
Reversing. Down from 27.6% for the full year 2025 and 30.1% in Q4 2025. This is the financial manifestation of the company's R&D and commercial buildout for breast cancer and minimal residual disease (MRD) markets.
Key Questions
Margin Trough Timing
With 2026 Adjusted EBITDA margin guided down to ~25%, should investors view 2026 as the absolute trough for profitability, or could the commercial scale-up for Prosigna and TrueMRD extend margin pressure into 2027?
New Product Revenue Milestones
The 2026 testing revenue guide strictly excludes new test contributions. What specific reimbursement or operational milestones must be cleared before management will layer Prosigna or TrueMRD revenue into the corporate outlook?
Capital Allocation with $413M in Cash
Operating cash flow is surging, leaving the balance sheet highly liquid. With no debt and margins intentionally depressed for organic investments, what is the appetite for M&A to accelerate pipeline timelines, versus initiating a share repurchase program?